R&D News | pharmaphorum

News

GSK claims a first with Jemperli in endometrial cancer

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.

News

Aiolos $245m Series A heads latest crop of biotech rounds

Biotech investment may be somewhat in the doldrums at the moment, but the sector continues to see a steady stream of deals – particularly in the venture capital category –

News

Early result backs Regeneron’s deafness gene therapy

Regeneron’s gene therapy for a profound form of deafness affecting children, DB-OTO, has shown the first signs that it can improve hearing in a clinical trial.

News

Sanofi will exit consumer health and boost R&D investment

Sanofi is following in the footsteps of a number of its peers in pharma with a plan to spin off its consumer health business into a separate company and focus its efforts

News

COVID, flu combo jab from Pfizer/BioNTech heads for phase 3

A combination COVID-19 and influenza vaccine being developed by Pfizer and BioNTech has generated immune responses against the viruses in a phase 1/2 trial, setting up a p

News

First data with subcutaneous Leqembi, and other CTAD news

Eisai and Biogen have reported data showing that a subcutaneous formulation of its Alzheimer’s disease therapy Leqembi matched the current intravenous version at clearing

GSK claims a first with Jemperli in endometrial cancer

Aiolos $245m Series A heads latest crop of biotech rounds

Early result backs Regeneron’s deafness gene therapy

Sanofi will exit consumer health and boost R&D investment

COVID, flu combo jab from Pfizer/BioNTech heads for phase 3

First data with subcutaneous Leqembi, and other CTAD news

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks